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Objective: Articular cartilage is a highly specialized tissue which forms the surfaces in synovial joints.
Full-thickness cartilage defects caused by trauma or microfracture surgery heal via the formation of
ﬁbrotic tissue characterized by a high content of collagen I (COL I) and subsequent poor mechanical
properties. The goal of this study is to investigate the molecular mechanisms underlying ﬁbrosis after
joint injury.
Design: Rat knee joint models were used to mimic cartilage defects after acute injury. Immunohisto-
chemistry was performed to detect proteins related to ﬁbrosis. Human fetal chondrocytes and bone
marrow stromal cells (BMSCs) were used to study the inﬂuence of the lipid lysophosphatidic acid (LPA)
on COL I synthesis. Quantitative PCR, ELISA and immunohistochemistry were performed to evaluate the
production of COL I. Chemical inhibitors were used to block LPA signaling both in vitro and in vivo.
Results: After full-thickness cartilage injury in rat knee joints, stromal cells migrating to the injury
expressed high levels of the LPA-producing enzyme autotaxin (ATX); intact articular cartilage in rat and
humans expressed negligible levels of ATX despite expressing the LPA receptors LPAR1 and LPAR2. LPA-
induced increases in COL I production by chondrocytes and BMSCs were mediated by the MAP kinase and
PI3 Kinase signaling pathways. Inhibition of the ATX/LPA axis signiﬁcantly reduced COL I-enriched
ﬁbrocartilage synthesis in full-thickness cartilage defects in rats in favor of the collagen II-enriched
normal state.
Conclusion: Taken together, these results identify an attractive target for intervention in reducing the
progression of post-traumatic ﬁbrosis and osteoarthritis.
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Pathological and disorganized regeneration of tissue in a vari-
ety of organs after injury often results in deposition of excessive
ﬁbrotic tissue with inferior biomechanical properties. Full-
thickness disruption of articular cartilage by trauma to synovial
joints is one example in which highly specialized hyaline cartilage
is replaced by biomechanically inferior, disorganized ﬁbrotic tissue
enriched in collagen type I (COL I). Such traumatic cartilage defects
often lead to degenerative joint disease or osteoarthritis1. One oftd. All rights reserved.
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defects is a bone marrow stimulation technique known as
microfracture surgery. In the procedure, a surgical awl is used to
create small holes in the subchondral plate, which allow bleeding
into the defect from the subchondral bone marrow2. Thus far, this
technique has demonstrated short-term clinical success in young
and active patients but not in older, more sedentary adults3. In the
process of healing, bone marrow stromal cells (BMSCs) migrate
into the site of injury and form ﬁbrocartilage, a scar-like tissue
composed predominantly of COL I and containing only modest
amounts of glycosoaminoglycans (GAGs) and collagen II (COL II)
that are typically present in normal hyaline cartilage. Fibro-
cartilage demonstrates poor mechanical properties, and its inte-
gration to native cartilage is insufﬁcient, often leading to
degeneration of the repaired tissue4 with subsequent deteriora-
tion and poorer clinical outcomes over the long term. The mech-
anisms by which BMSCs in the defect deposit disproportionate
levels of disorganized COL I remain elusive. The identiﬁcation of
factors that drive the production of ﬁbrocartilage at the site of
repair represents is a major goal in the ﬁeld of cartilage regener-
ation. One of the major questions remaining in this ﬁeld is
whether the disorganized reparative ﬁbrocartilage generated by
full-thickness injury or microfracture is a result of (1) the limited
intrinsic capacity of BMSCs to differentiate into COL II-producing
chondrocytes or (2) the consequence of a pathological “niche” in
the site of cartilage injury.
We have recently identiﬁed lysophosphatidic acid (LPA) as a
novel potential regulator of COL I biosynthesis that may play a
mechanistic role in ﬁbrocartilage formation5. LPA is a small lipid
produced by an ectoenzyme autotaxin (ATX; also known as phos-
pholipase D) concentrated on the outward face of the plasma
membrane of articular chondrocytes and BMSCs6. The enzyme
belongs to the family of nucleotide pyrophosphatases/phosphodi-
esterases (NPPs) which convert lysophosphatidylcholine (LPC) into
LPA by cleavage of the choline group7. ATX knockout mice die at
E9.5 due to severely impaired vasculature formation in yolk sac and
embryo proper8.
One of the best-documented effects of LPA under pathological
conditions is excessive and disorganized COL I deposition in ﬁbrotic
tissue, leading to ﬁbrosis of the lung, kidney, dermis and liver9e12.
Six G protein-coupled LPA receptors have been identiﬁed so far;
highly selective inhibitors for some of these receptors have been
successfully developed and tested both in vitro and in vivo13.
Pharmacological inhibitors of LPA signaling were found to prevent
ﬁbrotic transformation in several organs14, suggesting the possi-
bility that the same mechanism may play an important role during
reparative neo-chondrogenesis. Based on these data, we hypothe-
sized that the ATX/LPA axis is involved in ﬁbrocartilage formation
after full-thickness cartilage injury, and that the inhibition of LPA
signaling during reparative neo-chondrogenesis may reduce COL I
deposition and ﬁbrosis in injured joints.
Here we show that the ATX/LPA axis regulates the synthesis of
COL I in articular chondrocytes and BMSCs and that inhibition of
this pathway reduces ﬁbrocartilage formation following full-
thickness microfracture of articular cartilage in rats. These data
reveal a novel mechanism regulating cartilage healing and identify
an attractive molecular target to improve widely-used clinical
procedures for cartilage regeneration.
Methods
Animal model of cartilage defects in rat knee joints
Full-thickness (involving the subchondral bone) cartilage de-
fects were generated in the femoral intra-condylar region of aknee joint in rats using a previously described method15. Brieﬂy,
11e12 week old male SpragueeDawley rats (Charles River, San
Diego, CA) were anesthetized and medial para-patellar arthrotomy
was carried out under a dissection microscope (Olympus, USA).
One mm-wide osteo-chondral defects were made with a Kirschner
wire. At weeks 1, 2 and 4, rats were sacriﬁced and dissected for
histological examination. For the ATX/LPA inhibition experiments,
microspheres loaded with either BrP-LPA (“inhibitor” group,
N ¼ 4) or its analog (“vehicle” group, N ¼ 4) were injected in the
joints after closure of the arthrotomy but before skin closure. Local
administration of BrP-LPA was combined with systemic intraper-
itoneal (IP) injection of the drug at a dose 5 mg/kg carried out
every 3 days after surgery up to 21 days. Rats in “vehicle” group
received IP injection of physiological saline at the same time
points. Three weeks after surgery, rats of both groups were
sacriﬁced for examination.
Human biopsies, cell culture and expansion
The use of human material has been approved by the UCLA
Institutional Review Board. Fetal tissues were obtained from
Novogenix Laboratories, LLC (Los Angeles, CA) following informed
consent and anonymous donation. Articular chondrocytes were
extracted from epiphyseal regions of 17-week tissues as previously
described16. Sex of fetal samples were not determined. In short,
cartilagewas digested for 20e22 h in collagenase type II (0.15%w/v)
in DMEM supplemented with penicillin (100 U/mL) and strepto-
mycin (100 mg/mL). Chondrocytes were then cultured in chon-
drocyte expansion medium (DMEM/F12 supplemented with 10%
FBS and 100 U/mL penicillin and 100 mg/mL streptomycin). Medium
was refreshed every 3e4 days. Upon conﬂuence, chondrocytes
were sub-cultured. All reagents used for cell culture were pur-
chased from Invitrogen (Carlsbad, CA) unless otherwise stated.
Common chemicals were purchased from SigmaeAldrich. Adult
human cartilage and synovium tissue were obtained from The
National Disease Research Interchange (NDRI, Philadelphia, PA).
Three male donors were used in this study.
Fabrication of polymeric microspheres
PLGA (polylactic-co-glycolic acid) microspheres were fabricated
according to previously published methods17. Brieﬂy, 10% (w/v)
PVA (polyvinyl alcohol), 10% (w/v) PVP (polyvinyl pyrrolidone) and
2% (w/v) 50:50 PLGA solutions were mixed. Microspheres were
collected by centrifugation at 5000 RPM for 30 min. Microspheres
were loaded with BrP-LPA and re-suspended in DMEM and ster-
ilized by passing through 0.22 mm ﬁlters. Each animal received
100 ng of BrP-LPA loaded onto PLGA microspheres reconstituted in
10 mL of PBS. This solution was injected into the knee as described
above. Control animals were injected with microspheres prepared
without BrP-LPA. For drug release experiments, either BrP-LPA or
the ﬂuorescently tagged fatty acid C1-BODIPY 500/510 C12
(Invitrogen, Carlsbad, CA) was loaded onto the microspheres
during fabrication. Drug release pilot experiments were performed
ﬁrst with C1-BODIPY 500/510 C12 to study the kinetics of drug
release.
Knockdown of ATX by short hairpin RNA (shRNA) in fetal BMSCs
Four unique 29mer shRNA constructs against human ENPP2
(encoding ATX) were cloned into a lentiviral vector also expressing
green ﬂuorescent protein e GFP (Origene Technologies, Rockville,
MD). Lentiviral supernatants containing shRNA constructs were
packaged by triple transfection of HEK293T cells according to pre-
vious published protocols18. Fetal BMSCs were transduced by
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cells were sorted by FACS based on expression of GFP on day 7 after
transduction and expanded for several passages.
Statistics
Descriptive statistics were performed for each data set and the
data combined for collective analysis. Data was converted to graphs
with GraphPad Prism 5.0 (La Jolla, CA). Statistical analysis was
performed with SigmaStat software (Systat Software Inc., Rich-
mond, CA). Following descriptive statistics, Student's t-test was
used for two-group comparison and one-way ANOVA followed by
Dunnett's test was applied for multiple group comparisons. Data
are presented as mean with 95% conﬁdence interval.
Detailed methods are available in Supplementary Material.
Results
The LPA-producing enzyme ATX is minimally expressed in normal
human cartilage
To determine if the LPA signaling pathway may function during
normal chondrogenesis, we ﬁrst screened the expression of six LPA
receptors in fetal chondrocytes (FCH) and bone marrow stromal
cells (BMSC) by PCR. We found that LPA receptors 1 and 2 (LPAR 1
and 2) were the most abundant in FCH and BMSC (Fig. S1). Using
immunohistochemistry, we further examined the expression of the
two receptors in articular chondrocytes and synovial tissue at
various stages of human development and found that these two
major receptors for LPA were abundantly present on articular
chondrocytes and synovium [Fig.1(A) and (B)]. In contrast, ATXwas
minimally expressed by chondrocytes at all stages, although other
cell types including vascular cells evidenced abundant expression
[Fig. 1(A) and (C)]. Our previous studies showed high levels of ATX
expression by fetal and adult BMSCs5. To validate that these
expression patterns were maintained in culture, we assessed the
levels of ATX, LPAR 1 and LPAR 2 proteins on cultured primary
articular chondrocytes and BMSCs isolated from human fetal joints
[Fig. 1(D)]. We found that human BMSCs expressed ATX as well as
LPAR 1 and 2, while articular chondrocytes expressed the receptors
and minimally expressed ATX [Fig. 1(D)]. These data indicated that
articular chondrocytes both in vivo and in vitro have little capacity
to generate LPA, but do express the receptors required for
responding.
The ATX protein is highly expressed in osteo-chondral defects in the
rat knee
We hypothesized that the LPA pathway may inﬂuence ﬁbro-
cartilage formation after cartilage injury. To assess this, the rat knee
joint injury model was employed to study the levels of ATX
expression after full-thickness cartilage injury. In this system, cells
from the bone marrow migrate into the site of injury and form a
scar that repairs the defect but has poor mechanical properties.
Immunohistochemical staining conﬁrmed little ATX expression by
rat articular chondrocytes in uninjured joints [Fig. 2(A)]; however,
ATX was expressed at high levels by stromal cells ﬁlling the defect
at day 7 following injury [Fig. 2(B)]. The expression of ATX at day 14
and 28 after injury was signiﬁcantly lower than at day 7 [Fig. 2(C)
and Fig. S2].
Signiﬁcant COL I deposition at the site of cartilage injury was
clearly present at day 7 and further increased by day 14 [Fig. 2(B)
and (C)]. Loose connective tissue ﬁlling the defect contained small
blood vessels, as indicated by immunohistochemical staining for
CD146, which is expressed by perivascular cells (Fig. S3). By day 28,cartilage defects were ﬁlled with dense ﬁbrotic tissue strongly
positive for COL I (Fig. S2).
LPA stimulates COL I deposition by human chondrocytes and BMSCs
Next, we examined the effects of LPA on COL I deposition on
cultured primary human chondrocytes and BMSCs. Chondrocyte
pellets were cultured either in chondrogenic medium (control), in
chondrogenic medium containing LPA (LPA) or chondrogenic me-
dium containing both LPA and the chemical inhibitor BrP-LPA
(LPA þ BrP-LPA). BrP-LPA (1-Bromo-3(S)-hydroxy-4-[(palmitoy-
loxy)butyl]phosphonate) is an a-halo-substituted phosphonate and
a metabolically stable analog of LPA that has dual functions as an
antagonist against LPA receptors and an inhibitor for the lyso-
phospholipase D activity of ATX14. Due to its speciﬁc inhibitory
effects on ATX/LPA axis activity, it has been widely used to study to
therapeutic potential of blocking ATX/LPA signaling pathway19e21.
Results of histological examination indicated that both control and
LPA-treated samples deposited cartilaginous matrix strongly
stained with alcian blue [Fig. 3(A)]. However, LPA-treated pellets
produced high levels of COL I in addition to COL II, while control
pellets primarily expressed COL II [Fig. 3(A)].
Inhibition of the ATX/LPA axis by BrP-LPA reduced the deposi-
tion of COL I by chondrocytes in pellets as documented by ELISA
[Fig. 3(B)] and also decreased the size of the pellet [Fig. 3(D)]. After
normalization to DNA, LPA-treated pellets showed almost 3-fold
higher levels of COL I deposition compared to controls, while in-
hibition of the ATX/LPA axis abolished this increase. qPCR was
performed next to examine the ratio of COL II and COL I gene
expression in cultured pellets. After treatment with LPA, the COL II/
COL I ratio in chondrocyte pellets decreased in a dose-dependent
manner [Fig. 3(C)]. Despite the increase in COL I mediated by LPA,
no concomitant increase in matrix deposition of GAGs was
observed (Fig. S4). We next studied the effects of LPA on COL I
deposition by BMSCs. Since BMSCs have a considerable amount of
endogenous ATX activity, the effects of LPA were studied in the
presence of the ATX inhibitor S32826 (1 mM), which selectively
inhibits the activity of ATX but not the LPA receptors22. LPA treat-
ment resulted in almost 2-fold increase in COL I deposition by
BMSCs and increase in pellet size [Fig. 3(E) and (F)], which was
reversible by inhibiting the LPA receptors via BrP-LPA.
We then used shRNA to knock down the expression of ATX in
fetal BMSCs. Four lentiviral shRNA-GFP constructs (named shRNA-
A, -B, -C and eD) were delivered into cells via transduction; control
cells were transduced with lentiviruses carrying scrambled shRNA
and GFP sequences. To quantitate the amount of ATX activity pre-
sent following transduction, the ﬂuorogenic autotaxin substrate FS-
3 was used. FS-3 is a doubly labeled analog of the natural ATX
substrate LPC where in the ground, uncleaved state the ﬂuorophore
is quenched through intramolecular energy transfer. Once ATX
cleaves FS-3, the ﬂuorophore becomes liberated from the quencher,
resulting in increased ﬂuorescence23. This ﬂuorogenic assay indi-
cated that cells transduced with shRNA-B had the lowest enzymatic
activity of ATX [Fig. 4(A)]. Immunoﬂuorescent staining and qPCR
were performed next to test the expression of ATX on GFP-positive
cells sorted by FACS after transduction with shRNA-B vector. The
expression of ATX was decreased by shRNA-B construct, as indi-
cated by both immunoﬂuorescent staining [Fig. 4(B)] and qPCR
[Fig. 4(C)]. We then made pellets of control and shRNA-B trans-
duced cells. After 2 weeks culture in chondrogenic medium, ELISA
results indicated that deposition of COL I in pellets of shRNA-B
transduced cells was less than that of control cells [Fig. 4(D)].
Together, these data indicate that the LPA signaling axis may be
implicated in COL I deposition by BMSCs and chondrocytes at the
site of cartilage injury.
Fig. 1. ATX expression is limited to bone marrow stromal cells in normal human joints. (AeB) Human adult articular chondrocytes express minimal levels of ATX, while the LPA
receptors LPAR 1 and 2 are highly expressed by chondrocytes and synovial cells. One representative donor is shown (N ¼ 3, independent donors); positive signal is shown in brown.
(CeD) Fetal articular chondrocytes (FCH) do not express ATX but do express both LPAR1 and LPAR2; bone marrow stromal cells (BMSCs) express all three components of the ATX
pathway (N ¼ 3, independent donors). Positive signal is shown in brown (C) and red (D); cells are counterstained with hematoxylin (C) and DAPI (D), respectively. nv ¼ neural ﬁber,
bv ¼ blood vessel, Cart ¼ cartilage, Syn ¼ synovium; scale bars ¼ 50 mm. (E) Quantitative analysis of ATX and LPAR expression in fetal BMMSC and chondrocytes (passage 0e1). Data
were obtained from six technical replicates of one donor and presented as average and 95% conﬁdence interval of technical replicates.
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signaling pathways
To further characterize the downstream signaling pathways
involved in LPA-induced COL I deposition, cultured human chon-
drocytes were treated with LPA (1 mM) in the presence of selective
chemical inhibitors of signaling pathways previously shown to
regulate the intracellular activities of LPA24e26 [Fig. 5(A)]. To
quantitatively detect COL I deposition in the presence or absence of
the inhibitors, we used a recently developed method called Extra-
cellular Matrix Domain Detection (EMDD), which permits the
quantitative assessment of ECM production via ﬂow cytometry27.
COL I matrix domains were veriﬁed by immunoﬂuorescent staining
(Fig. S5) and quantiﬁed by ﬂow cytometry. As expected, LPA
treatment increased the percentage of chondrocytes depositing
COL I-positive matrix domains [Fig. 5(B) and (C)].Speciﬁc inhibitors for Gprotein interaction with LPA Gprotein-
coupled receptors (Pertussis toxin), PI3 kinase (PI828), and the
mitogen activated protein kinase (MAPK) pathway, including
MEK1/MEK2 (U0126) and p38 MAPK (SB230580), completely
abolished the increase of COL I production induced by LPA; se-
lective inhibitors for Phospholipase C (U73122) and Rho kinase
(Y27623) had minimal or no effect on LPA [Fig. 5(B) and (C)]. We
then focused on the PI3 kinase (PI3K) and MAPK pathways, as
they demonstrated the most prominent inhibition of COL I
deposition [Fig. 5(B) and (C)]. Using the same methods, we also
tested the effects of the inhibitors alone on COL I deposition. Our
data showed that PI3K or MAPK inhibitors signiﬁcantly reduced
the number of cells positive for COL I domains compared to
vehicle control, even in the absence of LPA, suggesting that these
signaling pathways are implicated in the regulation of COL I
biosynthesis (Fig. S6) by endogenous mediators. Next, we studied
Fig. 2. Fibrocartilage formation during the healing of full-thickness cartilage defects in rat knee joints. (A) Control rat knee joints only evidence ATX expression in bone
marrow stromal cells, while articular chondrocytes express collagen II (COL II) and low levels of collagen I (COL I). (B) Seven days after the creation of full-thickness defects, ATX and
COL I are abundantly expressed in the ﬁbrotic tissue. By day 14 after injury (C), ATX expression had decreased in the injured area, while a rich ﬁbrocartilaginous matrix highly
positive for COL I was deposited. Three rats were analyzed independently for each time point, with representative data shown. Arrows indicate higher magniﬁcation images of the
boxed area. Positive signal is shown in brown color, nuclei were counterstained with hematoxylin. Scale bars ¼ 50 mm.
L. Wu et al. / Osteoarthritis and Cartilage 23 (2015) 308e318312phosphorylation of PI3K and MAPK in chondrocytes in response
to LPA treatment at different time points by immunoﬂuorescent
staining using antibodies against phospho-PI3K and phospho-p38
MAPK. As shown in Fig. 5(D), phosphorylation of both kinases
peaked at 1 h after LPA treatment and remained high for p38
MAPK for up to 24 h, while phosphorylation levels of PI3K
steadily decreased after 2 h. These data independently validate
the increase in COL I following LPA treatment of chondrocytes and
identify the PI3K and MAPK signaling pathways as critical trans-
ducers of this effect.Pharmacological inhibition of the ATX/LPA signaling reduces COL I
synthesis and ﬁbrosis in osteo-chondral defects
Finally, we studied the effects of ATX and LPA inhibition on the
COL I deposition at the site of cartilage injury in vivo. BrP-LPA was
administrated via local intra-articular application using PLGA
microspheres loaded with BrP-LPA in combination with systemic
delivery of the drug via IP injection. Our data demonstrated that
PLGA microspheres loaded with a ﬂuorescent analog of LPA pro-
vide prolonged release of the drug for up to 7 days in culture
(Fig. S7). Control animals were injected with PLGA microspheres
without the drug and also given IP injections of physiological sa-
line. Three weeks post-surgery, COL I deposition in the defects was
markedly inhibited by BrP-LPA [Fig. 6(A)]. Notably, control defects
were ﬁlled with ﬁbrotic tissue rich in COL I ﬁbers with a minimal
cellular component, while BrP-LPA treated animals showed
signiﬁcantly higher numbers of cells expressing COL II but mini-
mal levels of COL I in the area of the defect [Fig. 6(A), (B) and (C)].
These experiments revealed signiﬁcant improvement of chon-
drogenesis though increased COL II deposition as well as reduction
of the excessive COL I ﬁbers in the site of injury in the presence of
BrP-LPA.Discussion
The data presented here deﬁne a direct mechanistic role of the
ATX/LPA axis in the regulation of COL I biosynthesis both in vitro
and in vivo in chondrocytes and BMSCs. Inhibitors of the MAPK and
PI3K signaling pathways abolished LPA-induced COL I deposition by
chondrocytes, indicating that both of these signaling pathways play
a role in transmitting the intracellular effects of LPA on COL I
biosynthesis. Our study also demonstrates that the ATX/LPA axis is
activated after acute full-thickness cartilage injury resulting in
deposition of ﬁbrotic tissue at the site of injury. Inhibition of the
ATX/LPA axis in injured rats signiﬁcantly improved chondrogenesis
at the site of injury, reducing COL I deposition and ﬁbrotic tissue
formation.
One of the major differences between ﬁbrocartilage and hyaline
cartilage is the composition and organization of collagen ﬁbers. The
reparative ﬁbrocartilage that ﬁlls full-thickness cartilage defects
contains very high levels of biologically inert and disorganized COL
I, while normal hyaline cartilage is primarily comprised of COL II. In
acute injury, COL I is secreted in large quantities as an important
component in scar tissue to ﬁll the gap in damaged tissue28.
However, rapid generation of biomechanically-inferior disorga-
nized ﬁbrotic tissue impairs the function of the organ and tissue
over the long term. Fibrocartilage has been shown to have inferior
biomechanical properties as compared to native hyaline cartilage
and this may explain why the clinical results of microfracture sur-
gery deteriorate with time29.
The MAPK and PI3K signaling pathways have been previously
shown to regulate COL I biosynthesis in various cells types. In the
current study, PI3K and p38 MAPK inhibitors signiﬁcantly reduced
COL I synthesis stimulated by LPA. Using a mouse model of injured
skeletal muscle, Li et al. demonstrated that the PI3K/Akt signaling
pathway plays an important role in scar tissue formation after acute
contusion in mouse skeletal muscle by increasing COL I production.
Fig. 3. LPA treatment increases COL I expression by cultured human chondrocytes and BMSC. (A) Chondrocyte pellets cultured in the presence of LPA for 3 weeks deposit
increased levels of COL I and reduced levels of COL II; inclusion of the LPAR/ATX inhibitor BrP-LPA prevents these changes. This effect was tested on four independent donors.
Representative pellets from one donor are shown. Scale bar ¼ 100 mm. (B) Quantitative analysis by ELISA demonstrated increased COL I in chondrocytes pellets cultured with LPA
and reversal of this effect when BrP-LPA was included. The levels of COL I were normalized to total DNA. Data were obtained from four independent donors, with two pellets per
donor (technical replicates) averaged for analysis, and presented as mean and 95% conﬁdence interval of biological replicates. (C) qPCR showed the ratio of COL II to COL I gene
expression decreased after LPA treatment in a dose-dependent manner. Three pellets per donor (four independent donors) were averaged for each biological replicate shown. Data
presented as mean and 95% conﬁdence interval of biological replicates. (D) Pellets treated with LPA were larger than controls. Three pellets (technical replicates) from each donor
were averaged to generate each data point, and four independent donors were tested. Data presented as mean and 95% conﬁdence interval of biological replicates. (E) Quantitative
analysis by ELISA demonstrated increased COL I in BMSC pellets cultured with LPA and reversal of this effect when BrP-LPAwas included. The levels of COL I were normalized to total
DNA. Two pellets per specimen were averaged as technical replicates for analysis, and data were obtained from four independent donors. Data presented as mean and 95%
conﬁdence interval of biological replicates. (F) BMSC pellets treated with LPA were larger in diameter than controls. Three pellets from each donor (technical replicates) were
measured for diameters and averaged, and three donors were tested independently. Data presented as mean and 95% conﬁdence interval of biological replicates.
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mation, which improved the function of injured skeletal muscle30.
Our study demonstrates that the MAPK and PI3K pathways are
implicated in the regulation of COL I biosynthesis by LPA in chon-
drocytes and may also be relevant targets to prevent ﬁbrocartilage
generation following injury or microfracture.
As one of the most popular bone marrow stimulation tech-
niques31, microfracture has been demonstrated to give good clin-
ical results in 60e80% of patients32,33. Evidence has shown thatpatients under 40 beneﬁt the most from microfracture, possibly
due to their intrinsically superior healing capacity as compared to
older patients and the larger pool of available progenitor cells34.
However, microfracture is a palliative procedure with clinical re-
sults deteriorating over time. Doubts remain over the durability of
the repaired tissue produced, which is ﬁbrocartilaginous and
therefore has inferior biomechanical properties compared with
hyaline tissue. Mithoefer et al. (2009) conducted a systematic re-
view examining the clinical efﬁcacy of microfracture in the knee,
Fig. 4. Knockdown of ATX by shRNA reduces COL I deposition in pellets of fetal BMSCs. (A) Fluorogenic autotaxin substrate FS-3 was added to the medium of fetal BMSCs
transduced by shRNA constructs. After 5 days, the ﬂuorescence intensity of medium was measured to reﬂect the activity of autotaxin. Total DNA was used for normalization. Data
were obtained from four independent donors with triplicate measurements averaged for each donor. Data presented as mean and 95% conﬁdence interval of biological replicates.
(B) The shRNA-B construct was lentivirally introduced into fetal BMSCs; GFP indicates the efﬁciency of transduction. Immunoﬂuorescent staining shows reduced levels of ATX in
transduced cells. Scale bars ¼ 50 mm. (C) qPCR showed that the expression of ENPP2 (encoding ATX) decreased after transduction with shRNA-B construct. Data were obtained from
one donor with three technical replicates. Data presented as mean and 95% conﬁdence interval of technical replicates. (D) Quantitative analysis by ELISA demonstrated decreased
COL I in pellets made by shRNA-B transduced BMSCs. The levels of COL I were normalized to total DNA. Data were obtained from four independent donors, with duplicate
measurements averaged for each donor. Data presented as mean and 95% conﬁdence interval of biological replicates.
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improved knee function during the ﬁrst 24 months post-
operation, but inconsistency in long term subjective outcomes35.
The current study describes a novel molecular mechanism regu-
lating COL I deposition by chondrocytes and BMSCs in injured
articular cartilage, which may potentially improve efﬁcacy of
microfracture. Reducing excessive COL I deposition and ﬁbro-
cartilage formation via the selective blockade of ATX/LPA signaling
may signiﬁcantly improve the quality of cartilage tissue formed
after microfracture surgery. Previously published data suggest that
paracrine interaction between chondrocytes and BMSCs may also
enhance cartilage regeneration via trophic/supportive effect of
BMSCs36e38 and it is interesting to speculate that reduction of
ﬁbrosis may indirectly contribute to this paracrine crosstalk.
Recently published reports also demonstrate that ATX is highly
upregulated in synovial ﬁbroblasts in animal models of inﬂam-
matory arthritis39. Conditional knockout of ATX in synovial
mesenchymal cells delays the process of rheumatic arthritis (RA) in
animal models40. As a major driving factor for this arthritic model,
tumor necrosis factor alpha (TNF-a) was shown to increase ATX
expression and stability. It is believed that the synergistic effect of
TNF-a on ATX expression is mediated by NF-kB signaling41. Not only
TNF-a, but also other inﬂammatory cytokines, are reported to in-
crease ATX expression42,43. Moreover, signiﬁcant amounts of ATX
were also detected in the serum, synovial ﬂuid and synovial ﬁ-
broblasts of human RA patients44. It is plausible to predict that LPA
may contribute to the pathogenesis of joint stiffness in this group of
patients as well. By selective inhibition of ATX/LPA signaling, therisks of developing RA due to exposure to inﬂammatory factors
after injury may be reduced.
Here we focused on the molecular mechanism of ATX/LPA
signaling in regulating collagen synthesis in human cells in vitro
and applying this knowledge to a rodent model of knee injury, and
there are clear limitations in this proof-of-concept study. One of the
main potential caveats to the data is the small sample size in both
in vitro experiments performed to deﬁne the effects of LPA inhibi-
tion on human cells, as well as in vivo studies to interrogate these
effects in a model of joint healing. The observed variation in the
human data could arise from potential gender differences in sam-
ples or genetic or environmental divergences. In parallel, variation
in the rat data obtained in vivo could result from the outbred ge-
netic background of SpragueeDawley rats; only males were used to
try and minimize additional gender-based differences in response
to LPA inhibition. Although there is clear variation between bio-
logical replicates in both types of data, the in vitro results are
convincing due to multiple inhibitors of the ATX/LPA signaling
cascade evidencing similar effects on collagen I production. The
degree to which these ﬁndings can be extended into human joints
based on the data presented here is limited; however, ongoing
studies are testing the efﬁcacy of ATX/LPA inhibition in preventing
ﬁbrosis and improving biomechanical function following full-
thickness injury in a porcine model. These studies are essential
due to differences in large and small mammal joint anatomy45, and
the results will be more translationally relevant. In addition, sub-
sequent mechanistic studies will deﬁne potential cross-talk be-
tween ATX/LPA and additional signaling pathways that may
Fig. 5. MAPK and PI3K signaling pathways mediate the effect of LPA on chondrocytes. (A) Signaling pathway inhibitors used in the study. Analysis of COL I levels on chon-
drocytes using ﬂow cytometry (B and C) revealed that chemical inhibitors of the p38 (SB230580), MEK/MEK2 (U0126) and PI3 (PI828) kinase pathways inhibited the increase of COL
I protein following LPA treatment. Pertussis toxin (inhibits interaction of G proteins with G protein-coupled LPA receptors) was used as a positive control. (C) Representative plots
from each experiment are shown. Data were obtained from three independent donors, with duplicate measurements averaged for each donor. Data presented as mean and 95%
conﬁdence interval of biological replicates. (D) LPA treatment induces activation of the p38 MAPK (phospho-p38) and PI3K (phospho-Akt) pathways. LPA treatment of chondrocytes
induced phosphorylation of p38 MAPK (red) and PI3K (green); activation of the PI3K pathway persisted longer after a single LPA treatment than MAPK. Nuclei are counterstained
with DAPI (blue). Scale bars ¼ 25 mm. Data presented as average and 95% conﬁdence interval. Fetal articular chondrocytes (passage 0e1) were derived from one donor, and ﬁve
technical replicates were performed. Data presented as mean and 95% conﬁdence interval of technical replicates.
L. Wu et al. / Osteoarthritis and Cartilage 23 (2015) 308e318 315promote ﬁbrocartilage formation. These data may illuminate other
clinically relevant targets for the prevention of osteoarthritis
following acute injury or microfracture surgery, possibly deﬁning
multimodal therapies to facilitate neo-chondrogenesis.In conclusion, the current study demonstrates that LPA
signaling plays a major role in the regulation of COL I biosynthesis
by articular chondrocytes and BMSC both in vivo and in vitro. Our
experimental data suggest that controlled inhibition of the ATX/
Fig. 6. Pharmacological inhibition of the ATX/LPA axis reduces COL I deposition at the site of joint injury. (A) Three weeks following full-thickness osteo-chondral defects, rat
knee joints treated with BrP-LPA showed less COL I accumulation and ﬁber formation while evidencing increased COL II deposition. Dashed line shows the initial site of injury.
Arrows indicate enlarged images of the boxed area. Scale bars ¼ 50 mm. (B) Quantitative analysis documented the concomitant decrease in COL I and (C) increase in COL II following
BrP-LPA treatment. Four rats (biological replicates) were analyzed independently (each rat represents two technical replicates as each had two cartilage defects) per group. For both
B and C, three sections were quantiﬁed from each of two defects or non-injured normal areas in each rat and averaged to generate the values for one rat. Data are shown as mean
and 95% conﬁdence interval of biological replicates.
L. Wu et al. / Osteoarthritis and Cartilage 23 (2015) 308e318316LPA axis may signiﬁcantly improve the quality of regenerated
cartilage tissue via reduced COL I production and ﬁbrosis in the site
of injury and thus improve the existing clinical approaches for
cartilage restoration.Author contributions
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